NCT04091217

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.

Detailed description

The study is divided into 2 stages. Stage I of the study is completed when 22 patients with measurable disease have been enrolled and completed ORR evaluation. If the number of responders in Stage I is more than 3, another 16 patients may be enrolled to Stage II.

Conditions

• Melanoma

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
DRUG	Bevacizumab	Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.

Timeline

• Start date: 2019-11-25
• Primary completion: 2022-08-31
• Completion: 2023-09-01
• First posted: 2019-09-16
• Last updated: 2024-10-24
• Results posted: 2024-10-24

Locations

3 sites across 1 country: China